The Half-life can change, it depends on the the type, but it can, currently leronlimab’s half life is listed (incorrectly) depending on the dose, which that chart I posted today indicates.

https://aidsinfo.nih.gov/drugs/423/leronlimab/0/professional

Quote:

---

Half-life (T½): In a study of multiple subcutaneous (SC) doses of leronlimab in adults with HIV, the mean terminal half-lives were 3.4 days (162 mg dose) and 3.7 days (324 mg dose).8 In a study of single intravenous (IV) doses of leronlimab in adults with HIV, the mean terminal half-lives were 3.13 days (5 mg/kg dose) and 3.33 days (10 mg/kg dose).9

---